New! Sign up for our free email newsletter.
Science News
from research organizations

Anticancer Drugs Might Be Of Benefit To Sickle-cell Patients

Date:
December 8, 2007
Source:
Journal of Clinical Investigation
Summary:
Although some individuals with the inherited blood disorder sickle cell disease benefit from treatment with hydroxyurea, which increases fetal hemoglobin expression, it does not work for all sickle-cell patients. Now, hope for a new therapy has been provided by the observation that the anticancer drugs lenalidomide and pomalidomide were more effective than hydroxyurea at inducing HbF expression by red blood cells derived in vitro from CD34+ cells from both healthy and sickle-cell individuals.
Share:
FULL STORY

Sickle cell disease (SCD) is an inherited blood disorder caused by a genetic mutation that leads to the generation of a mutant form of the beta-globin chain of hemoglobin (Hb).

Red blood cells containing Hb with this mutant beta-globin chain change shape upon deoxygenation and this causes them to get stuck in blood vessels, depriving the surrounding tissues of oxygen, which can lead to organ damage.

Although hydroxyurea, a treatment for SCD that works by increasing fetal Hb (HbF) expression, benefits some adults with moderate and severe SCD, it does not work for all individuals. Now, hope for a new therapy for SCD has been provided by the work of Laure A. Moutouh-de Parseval and colleagues working for Celgene Corporation.

In the study, lenalidomide and pomalidomide, immunomodulatory anticancer drugs, were both shown to be more effective than hydroxyurea at inducing HbF expression by erythrocytes derived in vitro from CD34+ cells from healthy individuals. In addition, the effects of pomalidomide and hydroxyurea on HbF expression were synergistic.

As pomalidomide was able to induce HbF expression in CD34+ cells from patients with SCD, the authors suggested that it might provide a new therapy for SCD, either alone or in combination with hydroxurea.

Furthermore, because the induction of HbF has been shown to be of some benefit to individuals with beta-thalassemia (a hereditary anemia caused by decreased beta-globin production), the authors also suggested that pomalidomide might be a good therapeutic for the treatment of beta-hemoglobinopathies other than SCD, such as beta-thalassemia.

Journal article: Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells, Journal of Clinical Investigation


Story Source:

Materials provided by Journal of Clinical Investigation. Note: Content may be edited for style and length.


Cite This Page:

Journal of Clinical Investigation. "Anticancer Drugs Might Be Of Benefit To Sickle-cell Patients." ScienceDaily. ScienceDaily, 8 December 2007. <www.sciencedaily.com/releases/2007/12/071207091936.htm>.
Journal of Clinical Investigation. (2007, December 8). Anticancer Drugs Might Be Of Benefit To Sickle-cell Patients. ScienceDaily. Retrieved December 11, 2024 from www.sciencedaily.com/releases/2007/12/071207091936.htm
Journal of Clinical Investigation. "Anticancer Drugs Might Be Of Benefit To Sickle-cell Patients." ScienceDaily. www.sciencedaily.com/releases/2007/12/071207091936.htm (accessed December 11, 2024).

Explore More

from ScienceDaily

RELATED STORIES